Full Terms & Conditions of access and use can be found at http://www.tandfonline.com/action/journalInformation?journalCode=irhe20 We thank Dr Roerdink and Dr Dietvorst for their insightful comments on our study (1) . One concern was that we did not differentiate between native joint infections and periprosthetic joint infections (PJIs). Because the pathology, treatment, and prognosis for septic arthritis (SA) in native joints differ significantly from those of PJIs, they suggested dividing the patients into two separate groups. Furthermore, they suggested differentiating between acute postoperative infections and chronic PJIs. Unfortunately, we are not able to differentiate between acute and chronic disease because according to Danish law (the Data Protection Agency), the data had been anonymized and therefore we could not gain access to the medical records. The descriptive and baseline characteristics of the patients with a native joint infection versus patients with a PJI are presented in Table 1 .
Regarding our secondary outcomes (microbiological aetiologies, systemic signs of inflammation, age, and comorbidities), Dr Roerdink and Dr Dietvorst really have a point because, according to Table 1 , there is a clear significant difference between the two groups, concerning age, systemic signs of inflammation [C-reactive protein, white blood cell count (WBC), and temperature], and the bacterial agent in synovial fluid. Coagulase-negative staphylococci are the main inhabitants of normal skin and mucosal flora, and have been identified as the major nosocomial pathogen associated with infections due to implanted medical devices, as a result of their great biofilm production capacity. There are significantly fewer infections caused by coagulasenegative staphylococci in the patients with native joints for this reason. On the other hand, two of the comorbidities listed (diabetes mellitus and other inflammatory diseases) are significantly more frequent in the patients with native joints. We did not find any difference in the 30 day mortality between the two groups.
Finally, while we are grateful for the comments, we would like to correct a misunderstanding. We did not measure the WBC in the synovial fluid, but in the peripheral blood.
In conclusion, we agree on the importance of distinguishing between SA in a native joint and an infection in a prosthetic joint. 
